Skip to main content
Erschienen in:

01.12.2015

Therapie der Hepatitis C Virusinfektion

verfasst von: Clarissa Freissmuth, Peter Ferenci, Ao. Univ. Prof. Dr. Harald Hofer

Erschienen in: Wiener klinische Wochenschrift Education | Ausgabe 3-4/2015

Einloggen, um Zugang zu erhalten

Auszug

Die Therapie der chronischen Hepatitis C hat in den letzten Jahren große Weiterentwicklungen erfahren. Mittels antiviraler Therapie kann die chronische Virusinfektion mittlerweile in der überwiegenden Mehrzahl der Patienten dauerhaft ausgeheilt werden. Langjährige Säulen der antiviralen Therapie wie Interferon, Steuerung der Therapiedauer nach initialem Ansprechen („response guided therapy“), Bestimmung des IL-28B Genotyps oder die Durchführung einer Leberbiopsie sind mit der Verfügbarkeit von neuen direkt antiviral wirksamen Substanzen zunehmend in den Hintergrund geraten. Mit der Zulassung der direkt antiviralen Substanzen kam es auch zu einer deutlichen Erweiterung des Spektrums der Behandlung von Patienten mit chronischer Hepatitis C, da auch Patienten mit fortgeschrittener Lebererkrankung oder Kontraindikationen gegen Interferon überaus wirkungsvoll und sicher therapiert werden können.
Die Therapie der chronischen Hepatitis C hat in den letzten Jahren große Fortschritte gemacht
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.CrossRefPubMed Larghi A, Zuin M, Crosignani A, et al. Outcome of an outbreak of acute hepatitis C among healthy volunteers participating in pharmacokinetics studies. Hepatology. 2002;36:993–1000.CrossRefPubMed
2.
Zurück zum Zitat Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–33.CrossRefPubMed Santantonio T, Fasano M, Sinisi E, et al. Efficacy of a 24-week course of PEG-interferon alpha-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance. J Hepatol. 2005;42:329–33.CrossRefPubMed
3.
Zurück zum Zitat Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73:387–91.CrossRefPubMed Lehmann M, Meyer MF, Monazahian M, et al. High rate of spontaneous clearance of acute hepatitis C virus genotype 3 infection. J Med Virol. 2004;73:387–91.CrossRefPubMed
4.
Zurück zum Zitat Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–4.CrossRefPubMed Hofer H, Watkins-Riedel T, Janata O, et al. Spontaneous viral clearance in patients with acute hepatitis C can be predicted by repeated measurements of serum viral load. Hepatology. 2003;37:60–4.CrossRefPubMed
5.
Zurück zum Zitat Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: a high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–8.CrossRefPubMed Gerlach JT, Diepolder HM, Zachoval R, et al. Acute hepatitis C: a high rate of both spontaneous and treatment-induced viral clearance. Gastroenterology. 2003;125:80–8.CrossRefPubMed
6.
Zurück zum Zitat Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C-virus-specific T cell response kinetics. Hepatology. 2004;39:1721–31.CrossRefPubMed Kamal SM, Ismail A, Graham CS, et al. Pegylated interferon alpha therapy in acute hepatitis C: relation to hepatitis C-virus-specific T cell response kinetics. Hepatology. 2004;39:1721–31.CrossRefPubMed
7.
Zurück zum Zitat Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999;354:2119–24.CrossRefPubMed Thursz M, Yallop R, Goldin R, et al. Influence of MHC class II genotype on outcome of infection with hepatitis C virus. The HENCORE group. Hepatitis C European Network for Cooperative Research. Lancet. 1999;354:2119–24.CrossRefPubMed
8.
Zurück zum Zitat Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673–81.PubMedCentralCrossRefPubMed Spada E, Mele A, Berton A, et al. Multispecific T cell response and negative HCV RNA tests during acute HCV infection are early prognostic factors of spontaneous clearance. Gut. 2004;53:1673–81.PubMedCentralCrossRefPubMed
9.
Zurück zum Zitat Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142:78–85.CrossRefPubMed Beinhardt S, Aberle JH, Strasser M, Dulic-Lakovic E, Maieron A, Kreil A, Rutter K, Staettermayer AF, Datz C, Scherzer TM, Strassl R, Bischof M, Stauber R, Bodlaj G, Laferl H, Holzmann H, Steindl-Munda P, Ferenci P, Hofer H. Serum level of IP-10 increases predictive value of IL28B polymorphisms for spontaneous clearance of acute HCV infection. Gastroenterology. 2012;142:78–85.CrossRefPubMed
10.
Zurück zum Zitat Beinhardt S, Payer BA, Datz C, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59:972–7.CrossRefPubMed Beinhardt S, Payer BA, Datz C, et al. A diagnostic score for the prediction of spontaneous resolution of acute hepatitis C virus infection. J Hepatol. 2013;59:972–7.CrossRefPubMed
11.
Zurück zum Zitat Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20 year multicenter study. Hepatology. 2000;32:91–6.CrossRefPubMed Wiese M, Berr F, Lafrenz M, et al. Low frequency of cirrhosis in a hepatitis C (genotype 1b) single source outbreak in Germany: a 20 year multicenter study. Hepatology. 2000;32:91–6.CrossRefPubMed
12.
Zurück zum Zitat Nomura H, Tanimoto H, Nagahama T, et al. Short-term interferon-alfa therapy for acute hepatitis C. Hepatology. 2004;39:1213–9.CrossRefPubMed Nomura H, Tanimoto H, Nagahama T, et al. Short-term interferon-alfa therapy for acute hepatitis C. Hepatology. 2004;39:1213–9.CrossRefPubMed
13.
Zurück zum Zitat Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2014. pii: gutjnl-2014-306997. doi:10.1136/gutjnl-2014-306997. Rüeger S, Bochud PY, Dufour JF, Müllhaupt B, Semela D, Heim MH, et al. Impact of common risk factors of fibrosis progression in chronic hepatitis C. Gut. 2014. pii: gutjnl-2014-306997. doi:10.1136/gutjnl-2014-306997.
14.
Zurück zum Zitat Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344–50.CrossRefPubMed Stättermayer AF, Stauber R, Hofer H, Rutter K, Beinhardt S, Scherzer TM, Zinober K, Datz C, Maieron A, Dulic-Lakovic E, Kessler HH, Steindl-Munda P, Strasser M, Krall C, Ferenci P. Impact of IL28B genotype on the early and sustained virologic response in treatment-naïve patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2011;9:344–50.CrossRefPubMed
15.
Zurück zum Zitat Licata A, DiBona D, Schepis F, et al. When and how to treat acute hepatitis C. J Hepatol. 2003;39:1056–62.CrossRefPubMed Licata A, DiBona D, Schepis F, et al. When and how to treat acute hepatitis C. J Hepatol. 2003;39:1056–62.CrossRefPubMed
16.
Zurück zum Zitat Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–8.CrossRefPubMed Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med. 1986;315:1575–8.CrossRefPubMed
17.
Zurück zum Zitat Rutter K, Stättermayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41:521–31.CrossRefPubMed Rutter K, Stättermayer AF, Beinhardt S, Scherzer TM, Steindl-Munda P, Trauner M, Ferenci P, Hofer H. Successful anti-viral treatment improves survival of patients with advanced liver disease due to chronic hepatitis C. Aliment Pharmacol Ther. 2015;41:521–31.CrossRefPubMed
18.
Zurück zum Zitat van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93. doi:10.1001/jama.2012.144878.CrossRefPubMed van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308(24):2584–93. doi:10.1001/jama.2012.144878.CrossRefPubMed
19.
Zurück zum Zitat Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: results from QEST-1, a phase III trial. Lancet. 2014;384:403–13.CrossRefPubMed Jacobson IM, Dore GJ, Foster GR, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype 1 infection in treatment-naïve patients: results from QEST-1, a phase III trial. Lancet. 2014;384:403–13.CrossRefPubMed
20.
Zurück zum Zitat Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet. 2014;384:414–26.CrossRefPubMed Manns M, Marcellin P, Poordad FP, et al. Simeprevir (TMC435) with peginterferon/ribavirin for treatment of chronic HCV genotype-1 infection in treatment-naïve patients: results from QUEST-2, a phase III trial. Lancet. 2014;384:414–26.CrossRefPubMed
21.
Zurück zum Zitat Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic Hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic Hepatitis C infection. N Engl J Med. 2013;368:1878–87.CrossRefPubMed
22.
Zurück zum Zitat Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65. doi:10.1016/S0140–6736(14)61036–9. (Epub 2014 Jul 28).CrossRefPubMed Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384(9956):1756–65. doi:10.1016/S0140–6736(14)61036–9. (Epub 2014 Jul 28).CrossRefPubMed
23.
Zurück zum Zitat Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefPubMed Afdhal N, Zeuzem S, Kwo P, et al. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98.CrossRefPubMed
24.
Zurück zum Zitat Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRefPubMed Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection. N Engl J Med. 2014;370:1483–93.CrossRefPubMed
25.
Zurück zum Zitat Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefPubMed Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRefPubMed
26.
Zurück zum Zitat Bourliere M, et al. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014;60(Suppl 1):239A. Bourliere M, et al. An integrated safety and efficacy analysis of > 500 patients with compensated cirrhosis treated with ledipasvir/sofosbuvir with or without ribavirin. Hepatology. 2014;60(Suppl 1):239A.
27.
Zurück zum Zitat Bourliere M, et al. Sofosbuvir/Ledipasvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed to protease inhibitor based triple therapy. Hepatology. 2014;60:1270A. Bourliere M, et al. Sofosbuvir/Ledipasvir fixed dose combination is safe and efficacious in cirrhotic patients who have previously failed to protease inhibitor based triple therapy. Hepatology. 2014;60:1270A.
28.
Zurück zum Zitat Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMed Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983–92.CrossRefPubMed
29.
Zurück zum Zitat Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65.CrossRefPubMed Andreone P, Colombo MG, Enejosa JV, et al. ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97 % and 100 % sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection. Gastroenterology. 2014;147(2):359–65.CrossRefPubMed
30.
Zurück zum Zitat Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMed Poordad F, Hezode C, Trinh R, et al. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82.CrossRefPubMed
31.
Zurück zum Zitat Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefPubMed Sulkowski MS, Gardiner DF, Rodriguez-Torres M, et al. Daclatasvir plus sofosbuvir for previously treated or untreated chronic HCV infection. N Engl J Med. 2014;370:211–21.CrossRefPubMed
32.
Zurück zum Zitat Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMed Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med. 2013;368(20):1878–87.CrossRefPubMed
33.
Zurück zum Zitat Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.CrossRefPubMed Jacobson IM, Gordon SC, Kowdley KV, et al. Sofosbuvir for hepatitis C genotype 2 or 3 in patients without treatment options. N Engl J Med. 2013;368:1867–77.CrossRefPubMed
34.
Zurück zum Zitat Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefPubMed Zeuzem S, Dusheiko GM, Salupere R, et al. Sofosbuvir and ribavirin in HCV genotypes 2 and 3. N Engl J Med. 2014;370:1993–2001.CrossRefPubMed
35.
Zurück zum Zitat Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015. doi:10.1002/hep.27726. Nelson DR, Cooper JN, Lalezari JP, et al. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase 3 study. Hepatology. 2015. doi:10.1002/hep.27726.
36.
Zurück zum Zitat Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology. 2014;60:1275A. Gane EJ, Hyland RH, An D, et al. High efficacy of LDV/SOF regimens for 12 weeks for patients with HCV genotype 3 or 6 infection. Hepatology. 2014;60:1275A.
37.
Zurück zum Zitat Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129–30A. Pol S, Reddy KR, Baykal T, et al. Interferon-free regimens of ombitasvir and ABT-450/r with or without ribavirin in patients with HCV genotype 4 infection: PEARL-I study results. Hepatology. 2014;60:1129–30A.
38.
Zurück zum Zitat Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology. 2014;60(Suppl 1):321A. Kapoor R, Kohli A, Sidharthan S, et al. All oral treatment for genotype 4 chronic hepatitis C infection with sofosbuvir and ledipasvir: interim results from the NIAID SYNERGY trial. Hepatology. 2014;60(Suppl 1):321A.
39.
Zurück zum Zitat Beinhardt S, Peck-Radosavjevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of liver transplant patients with chronic hepatitis C. Transpl Int. 2015. doi:10.1111/tri.12577. Beinhardt S, Peck-Radosavjevic M, Hofer H, Ferenci P. Interferon-free antiviral treatment of liver transplant patients with chronic hepatitis C. Transpl Int. 2015. doi:10.1111/tri.12577.
Metadaten
Titel
Therapie der Hepatitis C Virusinfektion
verfasst von
Clarissa Freissmuth
Peter Ferenci
Ao. Univ. Prof. Dr. Harald Hofer
Publikationsdatum
01.12.2015
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift Education / Ausgabe 3-4/2015
Print ISSN: 1863-3579
Elektronische ISSN: 1863-3765
DOI
https://doi.org/10.1007/s11812-015-0072-7